CASI CASI Pharmaceuticals Inc

Price (delayed)

$1.53

Market cap

$213.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$147.76M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
CASI's revenue has soared by 132% YoY and by 15% QoQ
CASI's gross profit has soared by 57% QoQ
CASI Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 4.3% from the previous quarter
CASI's EPS is down by 4.5% since the previous quarter but it is up by 4.2% year-on-year
The debt has surged by 54% since the previous quarter
CASI Pharmaceuticals's net income has decreased by 16% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
139.8M
Market cap
$213.89M
Enterprise value
$147.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.14
Price to sales (P/S)
10.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.46
Earnings
Revenue
$17.47M
EBIT
-$53.73M
EBITDA
-$50.47M
Free cash flow
-$29.48M
Per share
EPS
-$0.46
Free cash flow per share
-$0.24
Book value per share
$0.72
Revenue per share
$0.14
TBVPS
$1.08
Balance sheet
Total assets
$148.09M
Total liabilities
$25.9M
Debt
$1.99M
Equity
$100.03M
Working capital
$79.04M
Liquidity
Debt to equity
0.02
Current ratio
8.93
Quick ratio
8.52
Net debt/EBITDA
1.31
Margins
EBITDA margin
-288.9%
Gross margin
50.5%
Net margin
-307.5%
Operating margin
-334%
Efficiency
Return on assets
-42.8%
Return on equity
-63.9%
Return on invested capital
-119.2%
Return on capital employed
-38.9%
Return on sales
-307.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
-4.38%
1 week
-10%
1 month
-3.77%
1 year
-39.04%
YTD
-48.14%
QTD
-36.25%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$17.47M
Gross profit
$8.82M
Operating income
-$58.35M
Net income
-$53.73M
Gross margin
50.5%
Net margin
-307.5%
CASI's revenue has soared by 132% YoY and by 15% QoQ
CASI's gross profit has soared by 57% QoQ
The net margin has increased by 50% year-on-year and by 3.6% since the previous quarter
CASI's operating margin is up by 47% YoY

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.14
P/S
10.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.46
CASI's EPS is down by 4.5% since the previous quarter but it is up by 4.2% year-on-year
The stock's P/B is 49% below its 5-year quarterly average of 4.2 and 39% below its last 4 quarters average of 3.5
The equity has increased by 42% year-on-year and by 23% since the previous quarter
CASI's revenue has soared by 132% YoY and by 15% QoQ
CASI's P/S is 45% below its last 4 quarters average of 19.7

Efficiency

How efficient is CASI Pharmaceuticals business performance
CASI's return on sales is up by 50% year-on-year and by 3.6% since the previous quarter
CASI's ROIC is up by 39% YoY and by 12% from the previous quarter
The return on equity has declined by 8% year-on-year

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
The total assets is up by 49% year-on-year and by 16% since the previous quarter
CASI Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 4.3% from the previous quarter
The debt is 98% smaller than the equity
The debt has surged by 54% since the previous quarter
The equity has increased by 42% year-on-year and by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.